Daré Bioscience DARE-HPV program advances with non-dilutive US government funding

• Daré Bioscience said its DARE-HPV program for persistent high-risk HPV is advancing with non-dilutive government funding.
• The company did not disclose the funding amount or the agency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180902PRIMZONEFULLFEED9811629) on August 18, 2026, and is solely responsible for the information contained therein.